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Lymphoma’ modern understanding 
• Lymphoma is any of a group of blood cell 
tumors that develop from lymphatic cells with 
the enlarged lymph nodes and signs and 
symptoms that may include enlarged lymph 
nodes, fever, night  drenching sweats, unintended 
weight loss, itching, and feeling tired 
• The two main categories of lymphomas 
are Hodgkin lymphomas (HL) and the non-
Hodgkin lymphomas (NHL) 
• The World Health Organization (WHO) includes 
two other categories as types of lymphoma: 
multiple myeloma and immunoproliferative 
diseases   
https://en.wikipedia.org/wiki/Lymphoma  
HODGKIN LYMPHOMA 
Hodgkin lymphoma (HL): 
definition 
• Hodgkin (Hodgkin's) lymphoma or Hodgkin's 
disease, is a type of the most curable forms of 
lymphoma, in which cancer originates from a 
specific type of white blood cells called 
lymphocytes 
• Hodgkin Lymphoma is named for Dr. Thomas 
Hodgkin, who first noted a trend of cancer cases 
in the lymph nodes in 1832 
• The disease was called Hodgkin's disease until it 
was officially renamed Hodgkin lymphoma in the 
late 20th century  
https://www.lls.org/lymphoma https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
Hodgkin lymphoma (HL): 
epidemiology   
Incidence of Hodgkin Lymphoma in the United States, 2000-2005, by age: an 
age-related bimodal incidence pattern in HL persists  
http://www.cancernetwork.com/articles/hodgkin-lymphoma-older-patients-uncommon-disease-need-study  
Hodgkin lymphoma (HL): 
risk factors and etiology  
• Epstein-Barr virus infection/mononucleosis (sometimes called mono for 
short) 
• Age (HL is most common in early adulthood (ages 15 to 40, especially in a 
person’s 20s) and in late adulthood (after age 55)) 
• Gender (HD occurs slightly more often in males than in females) 
• Geography (HD is most common in the United States, Canada, and 
northern Europe, and is least common in Asian countries) 
• Family history (brothers and sisters of young people with HD have a higher 
risk for Hodgkin disease) 
• Socioeconomic status (the risk is greater in people with a higher 
socioeconomic background) 
• HIV infection (the risk is increased in people infected with HIV) 
• In most cases, the etiology of HL is unknown 
 
http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-risk-factors  
Hodgkin lymphoma (HL): 
mechanisms 1 
The germinal-center derivation of Hodgkin and Reed-Stemberg cells in classic HL 
and lymphomatic and histiocytic cells in noduler lymphocyte-predominant HL 
http://www.medscape.com/viewarticle/559870_4  
Hodgkin lymphoma (HL): 
mechanisms 2 
A possible model of pathogenesis 
http://www.slideshare.net/tashagarwal/hodgkin-lymphoma-43956683  
Hodgkin lymphoma (HL): 
classification   
Four pathologic subtypes of HL based upon Reed–Sternberg cell morphology and the 
composition of the reactive cell infiltrate seen in the lymph node biopsy 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma#Classification  
Name Description 
Nodular 
sclerosing 
Is the most common subtype and is composed of large tumor nodules showing scattered 
lacunar classical RS cells set in a background of reactive lymphocytes, eosinophils and plasma 
cells with varying degrees of collagen fibrosis/sclerosis  
Mixed-
cellularity 
subtype 
Is a common subtype and is composed of numerous classic RS cells admixed with numerous 
inflammatory cells including lymphocytes, histiocytes, eosinophils, and plasma cells without 
sclerosis  
Lymphocyte-
rich 
Is a rare subtype, show many features which may cause diagnostic confusion with nodular 
lymphocyte predominant B-cell Non-Hodgkin's Lymphoma (B-NHL) 
Lymphocyte 
depleted 
Is a rare subtype, composed of large numbers of often pleomorphic RS cells with only few 
reactive lymphocytes which may easily be confused with diffuse large cell lymphoma  
Unspecified 
Hodgkin lymphoma (HL): 
classification   
the Ann Arbor staging classification scheme  
http://www.lymphomation.org/stage.htm  https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma#Classification  
I   - is involvement of a single lymph node region (I) (mostly the cervical region) or 
single extralymphatic site   
II  - is involvement of two or more lymph node regions on the same side of 
the diaphragm or of one lymph node region and a contiguous extralymphatic site 
III - is involvement of lymph node regions on both sides of the diaphragm, which 
may include the spleen and/or limited contiguous extralymphatic organ or site  
IV - is disseminated involvement of one or more extralymphatic organs 
Hodgkin lymphoma (HL):  
clinical presentation 1 
• The painless enlargement of one or more lymph nodes, or 
lymphadenopathy 
• Itchy skin 
• Night sweats 
• Red-coloured patches, easy bleeding and petechiae (low platelet count) 
• Cyclical high-grade (Pel-Ebstein or simply P-E) fever  
• Unexplained weight loss 
• Splenomegaly in about 30% of cases   
• Hepatomegaly in about 5% of cases 
• Pain following alcohol consumption    
• Lower back pain  
• Nephrotic syndrome   
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Hodgkin lymphoma (HL): 
clinical presentation 2 
Itchy skin 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Lump in Neck  On the left side of the patient's neck 
enlarged lymph node 
Hodgkin lymphoma (HL): 
clinical presentation 3 
Pel-Ebstein Fever 
http://3.bp.blogspot.com/-QPLZFoWiVvs/Ufp1Y44yiqI/AAAAAAAAAxM/5RvtHq3FGlY/s1600/Pel-Ebstein.png  
 
 
Hodgkin lymphoma (HL): 
diagnosis 1 
• HL must be distinguished from non-cancerous causes of lymph node swelling 
and from other types of cancer 
• Definitive diagnosis is by lymph node biopsy with microscopic examination: 
• effacement of the lymph node architecture by scattered large malignant 
Reed-Sternberg cells (RSC)  admixed within a reactive cell infiltrate of 
lymphocytes, histiocytes, eosinophils, and plasma cells  
• RSC are identified as large often bi-nucleated cells with prominent nucleoli 
and an unusual CD45-, CD30+, CD15+/- immunophenotype 
• in 50% of cases, the RSC are infected by the Epstein–Barr virus 
• the cell histology in HL is not as important as it is in non-Hodgkin's 
lymphoma 
• Blood tests are performed to assess function of major organs and to assess 
safety for chemotherapy 
• Positron emission tomography is used to detect small deposits that are not 
shown on CT scanning 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Hodgkin lymphoma (HL): 
diagnosis 2 
Reed-Sternberg cells 
http://library.med.utah.edu/WebPath/jpeg5/HEME045.jpg https://s-media-cache-ak0.pinimg.com/736x/ac/06/20/ac0620621ea55abba1545f8bdf0711ee.jpg   
 
 
Hodgkin lymphoma (HL): 
diagnosis 3 
Reed-Sternberg cells 
https://secure.health.utas.edu.au/intranet/cds/pathprac/Files/Cases/Lymphatic/Case76/Pictures76/M2.jpg  
 
 
Hodgkin lymphoma (HL): 
diagnosis  
A) Flow cytometric immunophenotyping identifies subtle involvement by lymphoma in 
a background of benign cells (red and blue cells) B): fluorescence in situ hybridization 
(FISH) is one of the laboratory methods for accurate classification of lymphoma 
https://www.mskcc.org/clinical-updates/diagnostic-accuracy-enhanced-genomic-profile-immunophenotyping  
 
 
Hodgkin lymphoma (HL): 
treatment   
• Treatment is tailored to HL type, disease stage, and an assessment of the 
risk of resistant disease  
• Patients with early stage disease are effectively treated with radiation 
therapy or chemotherapy: adding localised radiation therapy after the 
chemotherapy regimen controls the tumors better and provides a better 
chance for survival than chemotherapy alone 
• Patients of any stage with a large mass in the chest are usually treated 
with combined chemotherapy and radiation therapy, and stem cell 
transplantation 
• Radiation oncologists typically use external beam radiation therapy  
• The high cure rates and long survival of many patients has led to a high 
concern with late adverse effects of treatment, including cardiovascular 
disease and second malignancies such as acute leukemias, lymphomas, 
and solid tumors within the radiation therapy field 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Hodgkin lymphoma (HL): 
prognosis 
• Treatment of HL has been improving over the past few decades 
• New types of chemotherapy have indicated higher survival rates than have 
previously been seen, and the 5-year survival rate for those patients with 
a favorable prognosis was 98%, while that for patients with worse 
outlooks was at least 85% 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Hodgkin lymphoma (HL): 
clinical case 1 
• Lymphomas predominantly affect the lymph nodes but can present at 
unusual sites, which are termed as extranodal lymphomas 
• Involvement of the ocular adnexa is an extremely uncommon occurrence, 
which is usually seen in patients with HL 
• Doctors report herewith an unusual case of a 5-year-old child with HL and 
involvement of extraocular muscle leading to ptosis 
• The child was managed by alternating cycles of cyclophosphamide, 
vincristine, procarbazine and prednisolone and adriamycin, bleomycin, 
vinblastine, and dacarbazine 
• He had complete response to chemotherapy with resolution of ptosis 
http://dgcases.docguide.com/ptosis-rare-presentation-hodgkin-lymphoma  
 
 Ptosis 
Hodgkin lymphoma (HL): 
clinical case 2 
• The maxillary sinus is a rare anatomic site for HL 
• Lymphoma in a patient who presents with disease in an unusual site and 
without lymphadenopathy is difficult to diagnose 
• Doctors report the case of a 60-year-old woman who presented with nasal 
congestion and obstruction 
• Examination revealed an abnormal-appearing mucosa involving the 
maxillary sinus 
• The treatment commonly includes chemotherapy and radiotherapy, which 
yield excellent outcomes 
http://dgcases.docguide.com/hodgkin-lymphoma-maxillary-sinus-unusual-occurrence  
 
 HL of the maxillary sinus 
Hodgkin lymphoma (HL): 
clinical case 3a 
• In lymph nodes, HL can be distinguished from non-Hodgkin lymphoma 
(NHL) by the presence of Hodgkin and Reed-Sternberg cells that co-
express CD30 and CD15 
• However, anaplastic large cell lymphoma (ALCL) and diffuse large B-cell 
lymphoma (DLBCL) can show identical features, and some cases of 
classical HL lack CD15 expression, rendering them difficult to differentiate 
from CD30-positive NHL 
• The differential diagnosis of cutaneous HL similarly includes ALCL and 
DLBCL, and, additionally, tumors of mycosis fungoides 
• The classical HL is of B-cell origin in virtually all cases, and shows at least 
focal weak expression of the B-cell marker PAX5 and often focal weak 
expression and no expression of the B-cell markers Oct-2 and BOB.1, 
respectively  
http://dgcases.docguide.com/use-expanded-immunohistochemical-panel-distinguish-cutaneous-hodgkin-lymphoma-histopathologic  
 
 Distinguish cutaneous Hodgkin lymphoma from histopathologic 
imitators  
Hodgkin lymphoma (HL): 
clinical case 3b   
• All three of these markers are almost invariably absent in T-cell 
lymphomas and are strongly expressed in B-cell lymphomas 
• Doctors report a 40-year-old man with classical HL who developed 
cutaneous nodules 
• A biopsy from one revealed Hodgkin/Reed-Sternberg cells with a similar 
immunophenotype to the diagnostic lymph node biopsy, namely 
CD30+/CD15+, diffusely but weakly PAX5+, focally weakly Oct-2+ and 
lacking BOB.1 expression, thereby confirming a diagnosis of cutaneous HL 
• This is the first report of the expression pattern of the combination of 
PAX5, Oct-2 and BOB.1 in the context of cutaneous involvement by 
Hodgkin lymphoma 
http://dgcases.docguide.com/use-expanded-immunohistochemical-panel-distinguish-cutaneous-hodgkin-lymphoma-histopathologic  
 
 Distinguish cutaneous Hodgkin lymphoma from histopathologic 
imitators  
NON-HODGKIN LYMPHOMA 
Non-Hodgkin lymphoma (NHL): 
definition 
• Non-Hodgkin lymphomas (Non-Hodgkin’s 
lymphoma, Non-Hodgkin lymphomas, non-
Hodgkin disease - NHL) are diverse group 
of blood cancers  that include any kind 
of lymphomas except HL, and  vary significantly in 
their severity, from slow growing to very 
aggressive types  
• NHL affects the lymphatic system, generally 
develops in the lymph nodes and lymphatic 
tissues, and in some cases, involves bone marrow 
and blood 
https://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma https://www.lls.org/lymphoma   
non-Hodgkin lymphoma (NHL): 
epidemiology   
Percent of New Cases by Age Group: Non-Hodgkin Lymphoma 
http://seer.cancer.gov/statfacts/html/nhl.html#  
non-Hodgkin lymphoma (NHL): 
risk factors and etiology 1  
There are many types of NHL, and some of the risk factors and etiology  
factors have been linked only to certain types: 
• Getting older is a strong risk factor for NHL overall, with most cases 
occurring after 60s 
• The risk is higher in men than in women, but there are certain types that 
are more common in women 
• In the USA, whites are more likely than African Americans and Asian 
Americans to develop NHL 
• NHL is more common in developed countries 
• Some types of NHL that have been linked to specific infections are more 
common in certain parts of the world  
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
non-Hodgkin lymphoma (NHL): 
risk factors and etiology 2  
• Some chemicals (benzene and certain herbicides and insecticides) and 
some chemotherapy drugs may be linked with an increased risk of NHL  
• Studies of survivors of atomic bombs and nuclear reactor accidents have 
shown they have an increased risk of developing several types of cancer, 
including NHL 
• Patients treated with radiation therapy for some other cancers, have a 
slightly increased risk of developing NHL later in life  
• People with weakened immune system including people infected with HIV 
have an increased risk for NHL 
• Some genetic (inherited) syndromes can cause children to be born with a 
deficient immune system and a higher risk of developing NHL 
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
non-Hodgkin lymphoma (NHL): 
risk factors and etiology 3  
• Some autoimmune diseases (rheumatoid arthritis, systemic lupus 
erythematosus, Sjogren disease, gluten-sensitive enteropathy, and others) 
have been linked with an increased rate of NHL 
• Some types of infections may raise the risk of NHL in different ways 
• Some viruses (the human T-cell leukemia/lymphoma virus (HTLV-1) and 
the Epstein-Barr virus (EBV) and human herpes virus 8 (HHV8)) can 
directly affect the DNA of lymphocytes, helping to transform them into 
cancer cells 
• Some long-term infections (Helicobacter pylori, Chlamydophila psittaci, 
Campylobacter jejuni) may increase a person’s risk of NHL by forcing their 
immune system to be constantly activated 
• The hepatitis C virus (HCV)  also can lead to the development of cancer, 
particularly hepatocellular carcinoma and non-Hodgkin lymphoma 
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
non-Hodgkin lymphoma (NHL): 
risk factors and etiology 4 
• Some studies have suggested that being overweight or obese may 
increase your risk of NHL 
• Other studies have suggested that a diet high in fat and meats may raise 
NHL risk 
• Some women develop anaplastic large cell lymphoma in the scar tissue 
around their breast implants 
http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-risk-factors  
Non-Hodgkin lymphoma (HL): 
mechanisms   
NHL does not involve Reed-Sternberg cells 
http://www.shaltech.com/about-lymphoma/  
non-Hodgkin lymphoma (NHL): 
classification  1 
The three most commonly used classification schemas for NHL are as follows: 
• National Cancer Institute’s Working Formulation (IWF) classified and grouped 
NHL by morphology and clinical behavior (i.e., low, intermediate, or high grade) 
with 10 subgroups labeled A to J 
• Revised European-American Classification of Lymphoid Neoplasms (REAL) 
attempted to apply immunophenotypic and genetic features in identifying 
distinct clinicopathologic NHL entities 
• World Health Organization (WHO) classification divides NHL into two groups: 
those of B-cell origin and those of T-cell/natural killer (NK)–cell origin 
 
http://emedicine.medscape.com/article/2500022-overview  
non-Hodgkin lymphoma (NHL): 
classification  2 
 National Cancer Institute’s Working Formulation (IWF) of NHL by clinical behavior: 
• Low-grade NHL subtypes: 
– A. Small lymphocytic, consistent with chronic lymphocytic leukemia 
– B. Follicular, predominantly small-cleaved cell 
– C. Follicular, mixed small-cleaved, and large cell 
• Intermediate-grade NHL subtypes: 
– D. Follicular, predominantly large cell 
– E. Diffuse, small-cleaved cell 
– F. Diffuse mixed, small and large cell 
– G. Diffuse, large cell, cleaved, or noncleaved cell 
• High-grade NHL subtypes 
– H. Immunoblastic, large cell 
– I. Lymphoblastic, convoluted, or nonconvoluted cell 
– J. Small noncleaved-cell, Burkitt, or non-Burkitt 
 http://emedicine.medscape.com/article/2500022-overview  
non-Hodgkin lymphoma (NHL): 
classification  3 
 Revised European-American Classification of Lymphoid Neoplasms (REAL): 
• The classification is comprehensive, including Hodgkin's and non-Hodgkin's 
lymphomas, as well as the lymphoid leukemias 
• Three major categories of lymphoid neoplasia were agreed upon: B-cell, 
T/natural killer (NK)-cell, and Hodgkin's disease 
• Within each of the major disease categories, the consensus panel recognized 
"definite," "provisional," and "unclassifiable" (not further classifiable) subsets 
• The classification is intended to be a flexible framework, subject to 
modification as new information and better understanding of the pathobiology 
ensues  
http://www.cancer.med.umich.edu/news/moj00fa4.shtml  
non-Hodgkin lymphoma (NHL): 
classification  4 
 World Health Organization (WHO) classification: 
 
B-cell neoplasms are as follows: chronic lymphocytic leukemia/small lymphocytic 
lymphoma, prolymphocytic leukemia, lymphoplasmacytic 
lymphoma/immunocytoma, Mantle cell lymphoma, follicular lymphoma, 
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphatic tissue 
(MALT) type, nodal marginal zone B-cell lymphoma (± monocytoid B cells), splenic 
marginal zone lymphoma (± villous lymphocytes), hairy cell leukemia, 
plasmacytoma/plasma cell myeloma, diffuse large B-cell lymphoma (DLBCL), 
Burkitt lymphoma  
http://www.cancer.med.umich.edu/news/moj00fa4.shtml  
non-Hodgkin lymphoma (NHL): 
classification  5 
 World Health Organization (WHO) classification: 
 
Peripheral T-cell and NK-cell neoplasms are as follows: T-cell chronic lymphocytic 
leukemia/prolymphocytic leukemia, T-cell granular lymphocytic leukemia, mycosis 
fungoides/Sézary syndrome, peripheral T-cell lymphoma not otherwise 
characterized, hepatosplenic gamma/delta T-cell lymphoma, subcutaneous 
panniculitis-like T-cell lymphoma, angioimmunoblastic T-cell lymphoma, 
extranodal T-/NK-cell lymphoma, nasal type, enteropathy-type intestinal T-cell 
lymphoma, adult T-cell lymphoma/leukemia (human T-lymphotrophic virus [HTLV] 
1+), anaplastic large cell lymphoma, primary systemic type, anaplastic large cell 
lymphoma, primary cutaneous type, aggressive NK-cell leukemia 
http://www.cancer.med.umich.edu/news/moj00fa4.shtml  
non-Hodgkin lymphoma (NHL):  
clinical presentation 1 
• The clinical presentation of NHL varies tremendously depending upon the 
their type and the areas of involvement 
• Some NHLs behave indolently with lymphadenopathy waxing and waning 
over years, and others are highly aggressive, resulting in death within 
weeks if left untreated 
• Indolent NHL are often insidious, presenting only with slow growing 
lymphadenopathy, hepatomegaly, splenomegaly, or cytopenias  
• Aggressive NHL commonly present acutely or subacutely with a rapidly 
growing mass, systemic B symptoms (i.e., fever, night sweats, weight 
loss), and/or elevated levels of serum lactate dehydrogenase and uric acid  
http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma  
 
 
non-Hodgkin lymphoma (NHL): 
clinical presentation 2 
Indolent NHL 
http://www.adamondemand.com/wp-content/themes/ADAMOnDemand2014/images/courses/screenshots/08035509/08035509_06.jpg  
 
 
non-Hodgkin lymphoma (NHL): 
clinical presentation 3 
Peripheral adenopathy in indolent NHL 
 https://quizlet.com/21608719/oncology-lymphomas-flash-cards/  
 
 
non-Hodgkin lymphoma (NHL): 
clinical presentation 4 
Aggressive NHL 
https://www.withfriendship.com/images/c/14437/Non-Hodgkin-lymphoma-picture.jpg  
 
 
non-Hodgkin lymphoma (NHL): 
clinical presentation 5 
Gingival appearance of patient with NHL 
http://exp-oncology.com.ua/article/3228/primary-extranodal-non-hodgkin-s-lymphoma-presenting-as-painful-gingival-swelling  
 
 
non-Hodgkin lymphoma (NHL): 
clinical presentation 6 
Spleen, NHL: uniform multicentric involvement of the white pulp by a malignant 
lymphoma 
http://2.bp.blogspot.com/-r0dcUiAFTB4/UXVoP3AC_KI/AAAAAAAAJuE/9al3qgWHV6g/s640/Spleen,+non-Hodgkin+lymphoma.png  
 
 
non-Hodgkin lymphoma (NHL): 
clinical presentation 6 
Cutaneous T-Cell NHL 
http://img.medscapestatic.com/pi/meds/ckb/55/36955tn.jpg  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 1 
• NHL is diagnosed by a tissue biopsy of an enlarged, painless lymph node, 
without of an infection 
• Patient will need some or all of the following tests depending on symptoms and 
the type of the NHL: 
• Lymph node biopsy  
• Imaging tests (X-rays, computed tomography (CT), positron emission 
tomography (PET), magnetic resonance imaging (MRI) 
• Blood tests  
• Bone marrow aspiration and biopsy 
• Liver and kidney function tests 
• Spinal tap (lumbar puncture)  
• Immunophenotyping of cells from a lymph node, blood or bone marrow to 
determine what type of non-Hodgkin's lymphoma cells are present. 
• Echocardiogram 
• Pulmonary function test 
http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/non-hodgkins-lymphoma/diagnosis/index.html  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 2 
Posteroanterior (PA) chest radiograph in a man with thoracic NHL shows 
mediastinal widening due to grossly enlarged right paratracheal and left 
paratracheal nodes 
http://emedicine.medscape.com/article/203399-workup#c9  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 3 
Posteroanterior (PA) chest radiograph in a 16-year-old male adolescent with 
thoracic NHL shows subtle enlargement of the lower paratracheal lymph nodes 
http://emedicine.medscape.com/article/203399-workup#c9  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 4 
Posteroanterior chest radiograph shows a large mass in the right parahilar region 
extending into the right upper and middle zones, with silhouetting of the right 
pulmonary artery: smaller mass is seen in the periphery of the right lower zone, 
that did not respond to a trial of antibiotics; core-needle biopsy of the larger lesion 
revealed NHL deposits in the lung 
http://emedicine.medscape.com/article/203399-workup#c9  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 5 
Extensive uptake in the mediastinal lymph nodes due to NHL 
http://emedicine.medscape.com/article/203399-overview  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 6 
Two sets of before and after FDG-PET scans of two patients with NHL treated with 
Zevalin or Bexxar   
http://www.cancernetwork.com/articles/snm-image-year-shows-radioimmunotherapy%E2%80%99s-effectiveness-against-non-hodgkin%E2%80%99s-lymphoma  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 7 
PET/CT images (coronal sections, display as virtual anatomy) using FDG of a patient 
with non-Hodgkin lymphoma before (left) and after (right) chemotherapy, showing 
complete response 
http://www.nature.com/onc/journal/v30/n40/fig_tab/onc2011169f2.html  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 8 
Coloured composite computed tomography (CT) and positron emission tomography 
(PET) scans of sections through a patient with growths in the abdomen and chest 
due to NHL 
http://www.nature.com/onc/journal/v30/n40/fig_tab/onc2011169f2.html  
 
 
non-Hodgkin lymphoma (NHL): 
diagnosis 9 
Diffuse large B-cell NHL 
http://img.medscapestatic.com/pi/meds/ckb/55/13655tn.jpg http://f.tqn.com/y/lymphoma/1/W/A/3/-/-/GettyImages-121823109.jpg  
http://www.humpath.com/IMG/jpg_spleen_gamma-delta_lymphoma_06_cd20.jpg  
 
 
Aggressive NHL Aggressive NHL 
non-Hodgkin lymphoma (NHL): 
treatment   
• The main types of treatment are chemotherapy ( intravenously e.g. CVP 
(cyclophosphamide,vincristine, prednisolone) with  monoclonal 
antibody drug rituximab, CHOP (cyclophosphamide, doxorubicin, 
vincristine and prednisolone), FAD (fludarabine, doxorubicin, 
dexamethasone), or FMD (fludarabine, mitoxantrone and 
dexamethasone), radiotherapy (often used as a local treatment), and 
biological (e.g. rituximab, ibritumomab, tositumomab, epratuzumab, 
alemtuzumab) therapy 
• Some people may have surgery to remove a tumour or the spleen 
• Sometimes high dose chemotherapy with a stem cell transplant may be 
used to try to increase the chance of curing NHL 
• Some people need only one type of treatment and others need more than 
one 
http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/treatment/types/  
 
 
non-Hodgkin lymphoma (NHL): 
prognosis 
• Survival rates for NHL vary widely, depending on the lymphoma type, 
stage, age of the patient, and other variables 
• According to the American Cancer Society, the overall 5-year relative 
survival rate for patients with non-Hodgkin’s lymphoma is 63% and the 10-
year relative survival rate is 51% 
• Survival rates for patients with NHL have greatly improved since the early 
1990s, especially for patients under age 45 
• Advances in treatment have contributed to this improvement 
http://www.nytimes.com/health/guides/disease/non-hodgkins-lymphoma/prognosis.html  
 
 
non-Hodgkin lymphoma (NHL): 
clinical case 1a 
• Primary central nervous system (CNS) NHL is a rarely encountered clinical 
entity 
• There is present a case of a primary CNS diffuse large B-cell non-Hodgkin's 
lymphoma developed on a previously operated and irradiated pituitary 
macroadenoma 
• 60-year-old woman presented with muscle weakness and eye lid ptosis 
• Thirty years ago, she was diagnosed with a non-functioning pituitary 
macroadenoma requiring repeated incomplete operations and 
conventional radiotherapy and accompanied by partial anterior pituitary 
deficiency 
• On admission, the magnetic resonance imaging (MRI) identified a pituitary 
sellar mass extending into the suprasellar region, compressing the optic 
chiasm and invading the left cavernous sinus 
http://dgcases.docguide.com/use-expanded-immunohistochemical-panel-distinguish-cutaneous-hodgkin-lymphoma-histopathologic  
 
 Primary pituitary NHL developed following surgery and 
radiation of a pituitary macroadenoma 
non-Hodgkin lymphoma (NHL): 
clinical case 1b 
• Following transsphenoidal surgery, the histological investigation revealed 
the presence of a diffuse large B-cell NHL without other loci from the 
systemic staging 
• Following chemotherapy and despite a marked resolution of the 
neoplastic pituitary mass in the post-chemotherapy MRI scan, the 
patient's course was complicated with consciousness deterioration 
attributed to epileptic seizures and she died of a hospital acquired 
infection 
• Clinicians should include primary CNS lymphoma in the differential 
diagnosis of an isolated invasive sellar mass 
• The possible association of primary CNS lymphoma development with the 
history of operated and irradiated pituitary adenoma is herein discussed 
http://dgcases.docguide.com/use-expanded-immunohistochemical-panel-distinguish-cutaneous-hodgkin-lymphoma-histopathologic  
 
 Primary pituitary NHL developed following surgery and 
radiation of a pituitary macroadenoma 
non-Hodgkin lymphoma (NHL): 
clinical case 2 
• Ataxia-telangiectasia is a multisystem, life-limiting, recessively inherited 
genetic disorder caused by mutations in the Ataxia-telangiectasia mutated 
gene 
• It is characterized by the onset of changes in neurological and 
immunological development, organ maturation in childhood, as well as a 
high incidence of malignancies 
• There is describe a case of an 11-year-old girl with a history of progressive 
ataxia and new finding of bilateral pelvic masses 
• Given an elevated alpha-fetoprotein, the pre-operative working diagnosis 
was a malignant germ cell tumor 
• Final ovarian pathology revealed a non-Hodgkin B-cell lymphoma with 
Burkitt-like morphology 
• It is the first case of a primary ovarian non-Hodgkin B-cell lymphoma in a 
child with Ataxia-telangiectasia 
http://dgcases.docguide.com/non-hodgkin-b-cell-lymphoma-ovary-child-ataxia-telangiectasia  
 
 NHL of the ovary in a child with Ataxia-telangiectasia 
MULTIPLE MYELOMA 
Multiple myeloma  (MM): 
definition 
• Multiple myeloma (plasma cell myeloma, 
myelomatosis, Kahler's disease - MM), is 
a cancer of plasma cells, in physiological 
conditions responsible for producing normal 
antibodies, wherein collections of their abnormal 
forms accumulate in the bone marrow and 
interfere with the normal blood cells 
• In most cases of MM abnormal plasma cells 
produce a paraprotein, which can cause kidney 
failure  
• Bone lesions in MM can lead to 
hypercalcemia (high blood calcium levels) 
https://en.wikipedia.org/wiki/Multiple_myeloma  
Multiple myeloma  (MM): 
epidemiology  1 
https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=254171  
Multiple myeloma  (MM): 
epidemiology  2 
Patients with MM 
http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/image/cases_crude_myeloma_png.png  
Multiple myeloma  (MM): 
epidemiology  3 
Patients with MM 
http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/image/world_inc_myeloma_png.png  
Multiple myeloma  (MM): 
risk factors and etiology  
• The risk of MM goes up as people age, most cases diagnosed at least after 
65 years 
• Men are slightly more likely to develop MM than women 
• MM is more than twice as common in African Americans than in white 
Americans, the reason is not known 
• Exposure to radiation may increase the risk of MM 
• Family history 
• Someone who has a sibling or parent with MM is 4 times more likely to 
get it than would be expected   
• Being overweight or obese increases a risk of developing MM 
• Having other plasma cell diseases 
• People with monoclonal gammopathy of undetermined significance 
(MGUS) or solitary plasmacytoma may will develop MM 
http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-risk-factors  
Multiple myeloma  (MM): 
mechanisms  1 
• B- lymphocytes start in the bone marrow and move to the lymph nodes 
• As they progress, they mature and display different proteins on their cell 
surface 
• B lymphocytes  activated to secrete antibodies are known as plasma cells 
• MM develops in B lymphocytes after they have left the part of the lymph node 
known as the germinal center 
• The normal cell line most closely associated with MM cells is generally taken to 
be either an activated memory B cell or the precursor to plasma cells, 
the plasmablast 
• The immune system keeps the proliferation of B cells and the secretion of 
antibodies under tight control 
https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology  
Multiple myeloma  (MM): 
mechanisms  2 
• When chromosomes and genes are damaged, often through rearrangement, 
this control is lost    
• The result is proliferation of a plasma cell clone and genomic instability that 
leads to further mutations and translocations 
• Production of cytokines (especially IL-6) by the plasma cells causes much of 
their localised damage, such as osteoporosis, and creates a microenvironment 
in which the malignant cells thrive 
• Angiogenesis (the attraction of new blood vessels) is increased. 
• The produced antibodies are deposited in various organs, leading to kidney 
failure, polyneuropathy and various other myeloma-associated symptoms. 
https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology  
Multiple myeloma  (MM): 
mechanisms  3 
 Manifestations of MM 
http://www.jahjournal.org/article.asp?issn=1658-5127;year=2015;volume=6;issue=2;spage=58;epage=63;aulast=Olaniyi  
Multiple myeloma  (MM): 
mechanisms  4 
 Bone marrow in MM 
http://www.themmrf.org/wp-content/uploads/healthy_bone-marrow-and-multiple-myeloma-bone-marrow.png  
Multiple myeloma  (MM): 
classification  1 
International Myeloma Working Group diagnostic criteria 
• Asymptomatic/smoldering myeloma: Monoclonal (M)-protein ≥ 30 g/L and/or 
bone marrow clonal cells ≥ 10% but no related organ or tissue impairment 
(ROTI) (end-organ damage) 
• Symptomatic myeloma: M-protein ≥ 30 g/L and/or bone marrow clonal cells ≥ 
10% and must have evidence of ROTI (end-organ damage) that can be 
attributed to the plasma cell proliferative process; manifested by CRAB 
(calcium, renal failure, anemia, and bone lesions: increased serum calcium ≥ 
11.5 mg/100 mL; renal insufficiency [serum creatinine > 1.73 mmol/L]; 
normochromic, normocytic anemia with a hemoglobin value > 2 g/100 mL 
below the lower limit of normal or a hemoglobin value < 10 g/100 mL; lytic 
lesions, severe osteopenia, or pathologic fractures) 
• Nonsecretory myeloma: Absence of an M-protein in the serum and urine, bone 
marrow plasmacytosis, and ROTI 
http://emedicine.medscape.com/article/2007195-overview  
Multiple myeloma  (MM): 
classification  2 
International Staging System 
 
• Stage I: Serum beta-2 microglobulin < 3.5 mg/L and serum albumin ≥ 3.5 g/dL 
• Stage II: Neither stage I nor stage III 
• Stage III: Serum beta-2 microglobulin ≥ 5.5 mg/L 
http://emedicine.medscape.com/article/2007195-overview  
Multiple myeloma  (MM):  
clinical presentation 1 
Signs and symptoms can vary and, early in the disease, there may be none. 
When signs and symptoms do occur, they can include: 
• Bone pain   
• Pathologic fractures   
• Spinal cord compression (back pain, weakness, numbness, or dysesthesias 
in the extremities) at multiple levels  
• Bleeding resulting from thrombocytopenia, and monoclonal protein 
absorption of clotting factors   
• Hypercalcemia (confusion, somnolence, bone pain, constipation, nausea, 
and thirst)   
• Infection through abnormal humoral immunity and leukopenia   
 
http://emedicine.medscape.com/article/204369-clinical  
 
 
Multiple myeloma  (MM):  
clinical presentation 2 
• Hyperviscosity (generalized malaise, infection, fever, paresthesia, sluggish 
mentation, sensory loss, headaches, somnolence, hazy vision, etc., when 
serum viscosity is greater than 4 times that of normal serum)  
• Neurologic symptoms (carpal tunnel syndrome, meningitis (especially that 
resulting from pneumococcal or meningococcal infection), some 
peripheral neuropathies, etc.) 
• Kidney problems, that can lead to symptoms like weakness, shortness of 
breath, itching, leg swelling 
• Anemia, which may be quite severe  
• Signs and symptoms of light chain amyloidosis (heart problems, enlarged 
liver and spleen, enlarged tongue, bleeding into the skin around the eyes 
(“raccoon eyes”),diarrhea)  
 
http://emedicine.medscape.com/article/204369-clinical  
 
 
Multiple myeloma  (MM): 
clinical presentation 3 
Herpes zoster 
(shingles) 
myelomapennstate.net/Contents/04c-ClinManifest.htm  linicalimagingscience.org/article.asp?issn=2156-7514;year=2013;volume=3;issue=2;spage=6;epage=6;aulast=Vinayachandran  
 
 
Amyloidosis infiltrating 
the tongue 
Swelling in the 
mandible 
Multiple myeloma  (MM): 
clinical presentation 4 
http://www.bloodjournal.org/content/120/1/20?sso-checked=true  
 
 
Cell dissemination and metastasis in 
MM: (A) Skeletal survey showing 
multiple lytic lesions in the skull 
B) A PET scan showing multiple areas 
of enhancement, indicating that MM 
cells can metastasize to areas outside 
the BM (C) Extramedullary MM 
presenting as a large subcutaneous 
mass on the shoulder (D) Circulating 
tumor plasma cells, demonstrating 
that a small number of tumor cells are 
continuously circulating in the 
peripheral blood leading to cell 
dissemination 
Multiple myeloma  (MM): 
diagnosis 1 
Diagnosis should be based on the following tests:  
• Detection and evaluation of the monoclonal (M-) component by serum and/or 
urine protein electrophoresis (concentrate of 24 h urine collection); 
nephelometric quantification of IgG, IgA and IgM immunoglobulins; 
characterisation of the heavy and light chains by immunofixation; and serum-
free light-chain (FLC) measurement  
• Evaluation of bone marrow (BM) plasma cell infiltration: BM aspiration and/or 
biopsies are the standard options to evaluate the number and characteristics. 
Moreover, the BM sample should be used for cytogenetic/fluorescence in 
situ hybridization (FISH) studies and also has the potential for 
immunophenotypic and molecular investigations   
 
 
http://www.esmo.org/Guidelines/Haematological-Malignancies/Multiple-Myeloma  
 
 
Multiple myeloma  (MM): 
diagnosis 2 
• Fluorodeoxyglucose positron emission tomography is currently under 
evaluation but should not be systematically used  
• Complete blood cell count, with differential   
• Serum creatinine and calcium level 
• Evaluation of lytic bone lesions: a radiological skeletal bone survey, including 
spine, pelvis, skull, humeri and femurs is necessary. A magnetic resonance 
imaging (MRI) or computed tomography (CT) scan may be needed to evaluate 
symptomatic bony sites, even if the skeletal survey is negative and the patient 
has symptoms suggesting bone lesions. Moreover, MRI provides greater detail 
and is recommended whenever spinal cord compression is suspected 
Fluorodeoxyglucose positron emission tomography is currently under 
evaluation but should not be systematically used 
http://www.esmo.org/Guidelines/Haematological-Malignancies/Multiple-Myeloma  
 
 
Multiple myeloma  (MM): 
diagnosis 3 
Diagram Distribution of MM 
http://radiopaedia.org/images/1696350  
 
 
Multiple myeloma  (MM): 
diagnosis 4 
http://radiopaedia.org/images/  
 
 
Multiple myeloma  (MM): 
diagnosis 5 
http://radiopaedia.org/images/  
 
 
Multiple myeloma  (MM): 
diagnosis 6 
http://radiopaedia.org/images/  
 
 
Multiple myeloma  (MM): 
diagnosis 7 
http://radiopaedia.org/images/  
 
 
Multiple myeloma  (MM): 
diagnosis 8 
http://emedicine.medscape.com/article/204369-overview  
 
 
Bone marrow aspirate demonstrating plasma cells of multiple myeloma 
Multiple myeloma  (MM): 
diagnosis 9 
• Genetic testing 
• Some myeloma centers now employ genetic testing, which they call a 
“gene array”  
• By examining DNA, oncologists can determine if patients are high risk or 
low risk of the cancer returning quickly following treatment 
• Cytogenetic analysis of myeloma cells may be of prognostic value, with 
deletion of chromosome 13, non-hyperdiploidy and the balanced 
translocations t(4;14) and t(14;16) conferring a poorer prognosis. The 
11q13 and 6p21 cytogenetic abnormalities are associated with a better 
prognosis  
• Prognostic markers such as these are always generated by retrospective 
analyses, and it is likely that new treatment developments will improve 
the outlook for those with traditionally "poor-risk" disease  
•   
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Multiple myeloma  (MM): 
diagnosis 9 
Genetic classifications of MM: the most commonly recognized high-risk 
genetic features are t(4;14) and del17p detected by FISH on either CD138-
selected BM cells, or with the identification of clonally restricted plasma cells 
staining for cytoplasmic light chain immunoglobulin 
http://www.bloodjournal.org/content/121/6/884?sso-checked=true  
 
 
Multiple myeloma  (MM): 
treatment  1 
• Treatment is focused on therapies that decrease the clonal plasma cell 
population and consequently decrease the signs and symptoms of disease 
• If the disease is completely asymptomatic (i.e. there is a paraprotein and 
an abnormal bone marrow population but no end-organ damage), 
treatment is typically deferred, or restricted to clinical trials 
• In addition to direct treatment of the plasma cell proliferation, 
bisphosphonates are routinely administered to prevent fractures  
• If needed, red blood cell transfusions or erythropoietin can be used for 
management of anemia 
• Bortezomib has the first therapeutic proteasome inhibitor approved by 
the U.S. FDA for treating relapsed multiple myeloma  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Multiple myeloma  (MM): 
treatment  2 
Initial therapy 
• High-dose chemotherapy (lenalidomide–dexamethasone, bortezomib 
based regimens, and lenalidomide–dexamethasone) with autologous 
hematopoietic stem-cell transplantation has become the preferred 
treatment for patients under the age of 65 
• Allogeneic stem cell transplantation, has the potential for a cure, but is 
used in a very small percentage of patients  
• Patients over age 65 and patients with significant concurrent illness often 
cannot tolerate stem cell transplantation, and for them the standard of 
care has been chemotherapy with melphalan and prednisone,  with 
bortezomib 
• Deep venous thrombosis and pulmonary embolism are the major side 
effects of high-dose chemotherapy  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Multiple myeloma  (MM): 
treatment  3 
Maintenance therapy 
• Sometimes after the initial treatment an ongoing maintenance therapy is 
offered 
• In younger patients, maintenance therapy with thalidomide appears to 
increase tumor burden reduction further, which translates into prolonged 
progression-free survival 
• Maintenance therapy with thalidomide, lenalidomide, or bortezomib is 
still of questionable benefit  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Multiple myeloma  (MM): 
treatment  4 
• Relapse 
• The natural history of MM is of relapse following treatment 
• For patients with relapsed disease, proteasome inhibitor bortezomib is a 
recent addition to the therapeutic arsenal (lenalidomide, thalidomide), 
especially as second line therapy  
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Multiple myeloma  (MM): 
treatment  5 
• Palliative care 
• Multiple national cancer treatment guidelines recommend early palliative 
care for people with advanced MM at the time of diagnosis as well as for 
anyone who has significant symptoms 
• Palliative care is appropriate at any stage of MM and can be provided 
alongside curative treatment 
• In addition to addressing symptoms of cancer, palliative care helps 
manage unwanted side-effects, such as pain and nausea related to 
treatments 
https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment  
 
 
Multiple myeloma  (MM): 
prognosis 
• With high-dose therapy followed by autologous stem cell transplantation, 
the median survival has been estimated  to be approximately 5 years 
• The International Staging System can help to predict survival  
• The prognoses for patients with MM, as those with other diseases, are not 
the same for everyone: older patients often are experiencing other serious 
diseases, which affect survival and younger patients might have much 
longer survival rates 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Multiple myeloma  (MM): 
clinical case 1  
• There was reported the case of a 71-year-old female patient affected by 
an extramedullary IgG-lambda multiple myeloma presenting as a pituitary 
mass lesion 
• Intrasellar plasmocytoma though rare, should be considered in the 
differential diagnosis of a pituitary mass lesion, since associated with 
different therapeutic and prognostic implications 
• Physicians should be alert for intrasellar plasma cell tumors in case of well 
preserved anterior pituitary function in combination with cranial nerve 
neuropathies and sellar destruction  
http://dgcases.docguide.com/extramedullary-multiple-myeloma-presenting-pituitary-mass-lesion  
 
 Extramedullary multiple myeloma presenting as a pituitary 
mass lesion 
Multiple myeloma  (MM): 
clinical case 2a  
• Bortezomib is a proteasome inhibitor and is active against MM 
• A 64-year-old Japanese man with MM received low-dose dexamethasone 
followed by bortezomib monotherapy as the initial therapy 
• He had no pulmonary complications during bortezomib treatment 
• Thereafter, he was treated with high-dose chemotherapy, followed by 
autologous peripheral blood stem cell transplantation 
• Ten months after autologous peripheral blood stem cell transplantation, 
his disease relapsed and he received bortezomib retreatment  
http://dgcases.docguide.com/bortezomib-induced-pneumonitis-during-bortezomib-retreatment-multiple-myeloma  
 
 Bortezomib-induced pneumonitis during bortezomib 
retreatment in MM  
Multiple myeloma  (MM): 
clinical case 2b  
• On the fifth day after the second dose of weekly bortezomib, he 
complained of mild dyspnea, dry cough and fever 
• High-resolution computed tomography of the chest showed bilateral 
infiltrates with partial ground glass appearance in the lower lobes 
• The diagnosis of bortezomib-induced pneumonitis was made 
• His bortezomib-induced pneumonitis responded to steroid therapy and his 
respiratory symptoms disappeared 
• So, careful management is needed during bortezomib retreatment, even 
after the previous course of bortezomib was administered safely 
http://dgcases.docguide.com/bortezomib-induced-pneumonitis-during-bortezomib-retreatment-multiple-myeloma  
 
 Bortezomib-induced pneumonitis during bortezomib 
retreatment in MM 
Prophylaxis 
• Prophylaxis is treatment that aims to stop a lymphoma elsewhere in the 
body  
• It can be difficult to treat once it develops, so sometimes needs a 
preventive treatment 
• This treatment may be given as well as the usual chemotherapy for the 
lymphoma or may already be part of a particular regimen  
https://www.google.com.ua/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=secondary+prophylaxis+of+lymphoma 
Abbreviations  
• CT         - computed tomography 
• EBV       - Epstein-Barr virus  
• FDA      - U.S. Food and Drug Administration  
• FISH     -fluorescence in situ hybridization   
• HCV      - hepatitis C virus  
• HHV8   - human herpes virus 8  
• HIV       - human immunodeficiency virus 
• HL         - Hodgkin lymphoma 
• HTLV-1 - human T-cell leukemia/lymphoma virus  
• IWF       - National Cancer Institute’s Working Formulation 
• MRI       - magnetic resonance imaging 
• NHL      - non-Hodgkin lymphoma 
• PET       - positron emission tomography 
• REAL     - Revised European-American Classification of Lymphoid Neoplasms  
• RSC       - Reed-Sternberg cells  
• WHO    - World Health Organization 
• MGUS  - monoclonal gammopathy of undetermined significance   
• MM      - multiple myeloma   
Diagnostic guidelines 
Europe 
• Best practice in lymphoma diagnosis and reporting 
• Control of pain in adults with cancer: a national clinical guideline   
• Referral guidelines for suspected cancer   
• Consensus recommendations for the management of cutaneous B-cell 
lymphomas   
• Diagnosis and treatment of primary CNS lymphoma in immunocompetent 
patients: guidelines from the European Association for Neuro-Oncology 
• Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up 
North America 
• NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma   
 
